Lupin arm gets USFDA nod to market bacterial infection generic tablets
As per IMS MAT June sales data, Zyvox tablets had US sales of $273.6 million

New Delhi: Drug major Lupin Wednesday said its subsidiary Gavis Pharmaceuticals has received approval from the US health regulator to market generic linezolid tablets used for treating bacterial infection in the American market.[caption id="attachment_2359544" align="alignleft" width="380"]
Reuters[/caption]The company's US-based subsidiary Gavis Pharmaceuticals has received final approval for its linezolid tablets in 600 mg strength from the US Food and Drug Administration (USFDA), Lupin said in a BSE filing.Gavis' product is a generic version of Pharmacia and Upjohn company's Zyvox tablets, which is indicated in adults and children for treatment of certain infections caused by susceptible gram-positive bacteria.As per IMS MAT June sales data, Zyvox tablets had US sales of $273.6 million.The stock ended 2.20 percent down at Rs 1,520.50 on BSE.

EU slaps Google with $1 billion antitrust fine over Play Store and Search practices
Brent crude flirts with $100, reigniting inflation and forex concerns for India
Can a record May offset a shrunk international schedule and help IndiGo turn a profit?
China has dominated Myanmar’s rare earth mines — now India eyes deal to harness country’s critical minerals
JPMorgan to hire 1,000 technology professionals for India GCCs amid AI-led transformation

